Make Your Provider Page Public with VaccineFinder!

Dear Immunization Partner,

The Philadelphia Department of Public Health (PDPH) and the CDC are requesting that you make your provider page in VaccineFinder public. VaccineFinder is the portal that you’re using to log your COVID-19 vaccine inventory every 24 hours and can be found here:

Making your provider page public will allow fellow Philadelphians to search for vaccine clinics near them and therefore make it easier for them to be vaccinated. Your public-facing page will not display inventory information (i.e., number of doses on hand). PDPH has created a training video, linked below, to help you complete this process if you need:

Click here to watch the VaccineFinder Training Video

Please include any information regarding registrations for vaccinations, including a phone number or scheduling link, if possible, on your display page so that members of the public can more easily schedule appointments. As distribution and eligibility expands, it is important to promote vaccine opportunities that are currently available. If your site has the capacity to accept walk-ins, please also include this information on your VaccineFinder page as we hope to continue improving accessibility to vaccinations across the city.

We understand that making your VaccineFinder page public, posting your registration information, and allowing walk-in appointments may raise concerns. If you or your site are concerned, feel free to reach out to a contact at PDPH or email and they will connect you with a PDPH staff member to help you address your concerns.

Thank you for all the hard work you are doing to vaccinate Philadelphians!

CDC and FDA Call for Pause of Use for Johnson & Johnson COVID-19 Vaccine

Attention all COVID-19 Vaccine Providers: The CDC and FDA have called for a pause of use for the Johnson & Johnson COVID-19 Vaccine. Please read the joint CDC and FDA statement below:

Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine

The following statement is attributed to Dr. Anne Schuchat, Principal Deputy Director of the CDC and Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research

As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen ) vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination. Treatment of this specific type of blood clot is different from the treatment that might typically be administered. Usually, an anticoagulant drug called heparin is used to treat blood clots. In this setting, administration of heparin may be dangerous, and alternative treatments need to be given.

CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases. Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution. This is important, in part, to ensure that the health care provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot.

Right now, these adverse events appear to be extremely rare. COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously. People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. Health care providers are asked to report adverse events to the Vaccine Adverse Event Reporting System at

CDC and FDA will provide additional information and answer questions later today at a media briefing. A recording of that media call will be available on the FDA’s YouTube channel.


Thank you for all you do to keep Philadelphia safe and healthy from COVID-19.

If you have any questions, please email

Remember to Submit Your Reconciliation With Your COVID-19 Vaccine Order!

All COVID-19 Vaccine Providers are required to submit an updated reconciliation the same day they place a COVID-19 vaccine order. Orders, temperature logs, and an up-to-date reconciliation must be submitted by Wednesdays at 5pm.

Moving forward, orders placed without a reconciliation will be rejected. It is each site’s responsibility to make sure that they are properly placing orders for COVID-19 Vaccine. This ensures that the vaccine ordering process is hassle free, and speeds up the vaccine rollout for everyone.

Additionally, please make sure your site is also reporting wastage by filling out our form for wasted vaccines.

Thank you for all you do to keep Philadelphia save and healthy from COVID-19.

If you have any questions, please email

Philadelphia is Now in Phase 1c!

Attention all COVID-19 vaccine providers! Philadelphia residents who fall under the phase 1c COVID-19 vaccine priority group are now eligible to be vaccinated. With this announcement the Philadelphia Department of Public Health (PDPH) acknowledges that a significant percentage of city residents in groups 1a and 1b have been vaccinated, and it is time to expand vaccine eligibility.

Click here to read more about Philadelphia’s Phase 1c expansion. 

Who qualifies for Phase 1c?

Starting this week, the following city residents are eligible to receive vaccine:

  • Sanitation workers
  • Maintenance and janitorial staff
  • Utility workers
  • Postal and package delivery workers

And starting on April 12th, we will expand eligibility to the remainder of phase 1c city residents. This includes:

  • Higher education staff
  • Finance: public facing, non-remote positions in the finance industry
  • Transportation workers such as airport and train workers and taxi or rideshare drivers
  • Construction workers
  • IT & telecommunications workers
  • Members of the press
  • Legal industry
  • Public health workers

Read more about phase eligibility here!

Phase 2 is on the Horizon

On April 19th, PDPH, in accordance with Federal guidance, will be opening vaccine to all city residents, regardless of priority group. While we still have time to prioritize those who are at greater risk of COVID-19 infection, let us double down on our efforts and work to get residents in phase 1c vaccinated!

Thank you for your hard work and efforts to vaccinate Philadelphia. In these past four months you have given over half a million people a dose of COVID-19 vaccine. Together we can keep Philly safe from COVID-19!

FDA Now Approves Use of the 11th Dose in Moderna Vials

Last week the U.S. Food and Drug Administration (FDA) announced a revision to their recommendations regarding the number of doses per vial available for the Moderna COVID-19 Vaccine. COVID-19 Vaccine Providers may now extract and use 11 doses from Moderna COVID-19 Vaccine vials. The updated guidance can be found here, or by clicking on the button below, and the press release announcing the change can be read on the FDA’s website here.

Ancillary Supply Kits

While the FDA now allows for the extraction of an 11th dose of Moderna Vaccine, the ancillary supply kits that arrive with your Moderna doses still only support the extraction of 10 doses. We will send an update on the ancillary supply kits, and their expansion for an 11th dose, when that information is available to us.

Reporting Wastage

Wasted doses will still be considered anything under 10 doses drawn per vial. Doses above the 10 doses per vial for Moderna should NOT be reported as wastage.

If you have any questions please contact the Philadelphia Immunization Program team at Thank you for the work that you do to keep Philadelphia safe and healthy!

Reminder: Check Your COVID-19 Vaccine Expiration Dates!

COVID-19 Vaccine Providers, please make sure you are checking the expiration dates of your COVID-19 Vaccine and using vials with sooner expiration dates first. 

If you have vaccine that is going to expire that you are not going to use, please let us know at least 2 weeks prior to expiration, so we can move it to a provider who can use it.

This ensures that no vaccine gets wasted, and that we can work together to efficiently vaccinate as many people as possible.

Here’s how to find the expiration date of the different COVID-19 Vaccine Brands

Pfizer: Vials stored in an utlracold storage unit can be used until the last day of the month printed on the tray and each vial.

Moderna: The expiration date for doses stored in the freezer can be acquired on the Moderna website by entering the lot number that is  printed on the box:

Janssen: The expiration date can be acquired three ways:

  • Scan the QR code on the outer carton
  • Call 1-800-565-4008
  • Visit

We may also be able to transfer unopened vials of Pfizer and Moderna that have been moved to refrigerated temperatures and are nearing their beyond use date (BUD).

To inquire about transferring expiring doses, please email with transfer in the subject.

Call to Action: Prioritize 65+ Population for COVID-19 Vaccine

Health departments across the country are seeing a new wave of COVID-19 cases. The Philadelphia Department of Public Health (PDPH) is seeing this same rise reflected in a distinct upward trend in our city. Despite Philadelphia being on the verge of expanding their priority populations for COVID-19 vaccine distribution, there are many highly vulnerable Philadelphians who still need their COVID-19 vaccine.

To reduce mortality within this new wave of cases, PDPH wants all COVID-19 Vaccine Providers to prioritize vaccinating Philadelphia residents 65 years of age and older.

As you know, vaccination is our best tool to fight the COVID-19 pandemic. Yesterday, the CDC released the results from a real world study that show the clear benefits of vaccinations across 4,000 individuals in 6 states.

By vaccinating the city’s most vulnerable residents, you are saving lives in Philadelphia.  

Thank you for continued work to keep our city safe and healthy. If you have any questions, please email

Persons Authorized to Administer COVID-19 Vaccinations

Who can administer COVID-19 Vaccine in Pennsylvania?

Below is a comprehensive list of all potential COVID-19 vaccinators in Pennsylvania, by license type as of February 9th, 2021. The chart is broken down by license and the PA legal authority that is applicable to whether they may be able to administer vaccines.

There are other licenses that can have their scope of practice incorporate additional skills, such as an emergency medical responder, if the skills are approved by the Department and are published in the Pennsylvania Bulletin. 28 Pa. Code section 1023.24.  Possible amendments to the PREP Act may also expand the ability of a license to administer vaccines in the Commonwealth.

To view or download a pdf copy of the document, please click here.


Specific COVID-19 Vaccine FAQ Sheets

The Philadelphia Immunization Program has received many questions from residents about the Pfizer and Moderna COVID-19 Vaccines. It the vaccine safe? Is it effective? What are the side effects? Different residents have different needs and we recognize that it is important to have specific FAQs that address specific questions for different populations and workforces.

In addition to the General COVID-19 Vaccine FAQ sheet, the Philadelphia Immunization program has also created specific COVID-19 FAQ sheets for childcare workers, congregate living facility staff and residents, essential workers, food service workers, long term care facility (LTCF) staff and residents, pregnant people, and public transit workers. These specific FAQ sheets are also translated into seven different languages. Please use the quicklinks below to click on the specific FAQ sheet you wish to download.

  1. Childcare Workers
  2. Congregate Living Facility Staff and Residents
  3. Essential Workers
  4. Food Service Workers
  5. Long Term Care Facility (LTCF) Staff and Residents
  6. Pregnant People
  7. Public Transit Workers


Childcare Workers COVID-19 Vaccine FAQ Sheet

Go back to quicklinks.


Congregate Living Facility Staff and Residents COVID-19 Vaccine FAQ Sheet

Go back to quicklinks.


Essential Workers COVID-19 Vaccine FAQ Sheet

Go back to quicklinks.


Food Service Workers COVID-19 Vaccine FAQ Sheet

Go back to quicklinks.


Long Term Care Facility (LCTF) Staff and Residents COVID-19 Vaccine FAQ Sheet

Go back to quicklinks.


Pregnant People COVID-19 Vaccine FAQ Sheet

Go back to quicklinks.


Public Transit Workers COVID-19 Vaccine FAQ Sheet

Go back to quicklinks.


General COVID-19 Vaccine FAQ Sheet

The Philadelphia Immunization Program has received many questions from residents about the Pfizer and Moderna COVID-19 Vaccines. It the vaccine safe? Is it effective? What are the side effects?

To help answer these questions, we have created a General COVID-19 Vaccine FAQ sheet in seven different languages. The FAQ sheet compiles the ten most frequently asked questions about the Pfizer and Moderna COVID-19 vaccine by Philadelphia residents. Please select and download one of the files below and share it among your network.

PDPH has also created more specific FAQ sheets for childcare workers, congregate living facility staff and residents, essential workers, food service workers, long term care facility (LCTF) staff and residents, pregnant people, and public transit workers. Please click here to access the specific FAQ sheets.

Don’t see your question listed? Please visit the city’s COVID-19 webpage for more FAQs and updates about the vaccine. Thank you for all you do to help keep Philadelphia safe and healthy!

COVID-19 FAQ Sheet for Long Term Care Facilities

Phase 1b of the city’s COVID-19 vaccine distribution plan includes residents over the age of 75. The Philadelphia Immunization Program is working with the city’s long term care facilities (LTCFs) to roll out COVID-19 vaccine distribution to this vulnerable population.

In conversation with our LTCF partners, we have heard many questions from residents and staff. It the vaccine safe? Is it effective? Will my medication interact with the vaccine? What are the side effects?

To help answer these questions, we have created a COVID-19 Vaccine FAQ Sheet in seven different languages.  The FAQ sheet compiles the ten most frequently asked questions about the COVID-19 vaccine by LTCF residents and staff. Please select and download one of the files below and share it among your network.

Don’t see your question listed? Please visit the city’s COVID-19 webpage for more FAQs and updates about the vaccine. Thank you for all you do to help keep Philadelphia safe and healthy!

Healthcare Workers Seeking COVID-19 Immunization

Healthcare Workers Seeking COVID-19 Immunization

To download a pdf copy of the document, please click here.

Immunization with a safe and effective COVID-19 vaccine is a critical component of the national strategy to reduce morbidity and mortality from the SARS-CoV-2 virus, and to help restore societal functioning. While the goal is to offer COVID-19 vaccine to all people who wish to be vaccinated, there is currently a limited supply of vaccine available. Initial vaccination efforts are focusing on healthcare workers who have a high risk of exposure to the virus and are at risk of transmitting infection to vulnerable persons. Residents of longterm care facilities are also a top priority. If you are a healthcare worker with both a risk of exposure and a risk of transmitting COVID-19, you are eligible to receive COVID-19 vaccination, as follows:

  • If you are affiliated with a Philadelphia hospital or health system, check with their Occupational Health Services to learn when vaccine will be made available to your practice.
  • If you are not affiliated with a hospital or health system, you will be able to receive vaccine through a local Pharmacy, Clinic, or Urgent Care. Access to vaccine at these sites will be appointment-based and for Philadelphia providers only. The ultracold storage requirements of Pfizer COVID vaccine makes this impossible to provide in these types of venues. When another product becomes available, it will be made available. Check back weekly for updates.
  • If you are not affiliated with a hospital or health system, and have a large practice (>100 employees), you may be eligible to receive a direct shipment of vaccine for your employees. To qualify for receiving shipped vaccine, you must: (1) be located in Philadelphia; (2) sign and submit the CDC Provider Agreement form at ; and (3) be able to transmit electronic vaccine administration records to the city’s data system (submit inquiry to


If you have any questions, contact our team at

Enroll your site to be a COVID-19 Vaccine Provider

COVID-19 Vaccine Provider Agreement Form

Our COVID-19 Provider Agreement form is here!

All sites intending to distribute COVID-19 vaccine must enroll as a provider. All medical facilities who regularly provide vaccine are eligible to enroll into our COVID-19 vaccine program.

Please refer to our Provider Agreement Guide to enroll as a provider for the COVID-19 vaccine.

Please review the Provider Agreement Guide in its entirety before filling out the agreement form and survey.

The agreement and survey form can be accessed here.

If you have any questions, contact our team at

ACIP Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine

12/13/2020 The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020. 

Below is a summary of the report. To read the report in full, please click here.

On December 11, 2020, the Food and Drug Administration issued an Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine. On December 12, 2020, after an explicit, evidence-based review of all available data, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years for the prevention of COVID-19. The recommendation for the Pfizer-BioNTech COVID-19 vaccine should be implemented in conjunction with ACIP’s interim recommendation for allocating initial supplies of COVID-19 vaccines.

Vaccinating Pregnant and Lactating Patients Against COVID-19

12/13/2020 Vaccinating Pregnant and Lactating Patients Against COVID-19

Below is an excerpt from the American College of Obstetricians and Gynecologist’s (ACOG) recommendations for vaccinating Pregnant and Lactating Patients against COVID-19. To read the full article, click here.

ACOG Recommendations

Pregnant Individuals

ACOG recommends that COVID-19 vaccines should not be withheld from pregnant individuals who meet criteria for vaccination based on ACIP-recommended priority groups. While safety data on the use of COVID-19 vaccines in pregnancy are not currently available, there are also no data to indicate that the vaccines should be contraindicated, and no safety signals generated from DART studies for the Pfizer-BioNtech vaccine. Therefore, in the interest of allowing pregnant individuals who would otherwise be considered a priority population for a vaccine approved for use under EUA, make their own decisions regarding their health, ACOG recommends that pregnant individuals should be free to make their own decision in conjunction with their clinical care team.

Individuals considering a COVID-19 vaccine should have access to available information about the safety and efficacy of the vaccine, including information about data that are not available. A conversation between the patient and their clinical team may assist with decisions regarding the use of vaccines approved under EUA for the prevention of COVID-19 by pregnant patients.  Important considerations include the level of activity of the pandemic in the community, the potential efficacy of the vaccine, the potential risk and severity of maternal disease, including the effects of disease on the fetus and newborn, and the safety of the vaccine for the pregnant patient and the fetus. While a conversation with a clinician may be helpful, it should not be required prior to vaccination as this may cause unnecessary barriers to access.

Clinicians should review the available data on risks and benefits of vaccination with pregnant patients, including the risks of not getting vaccinated in the context of the individual patient’s current health status, and risk of exposure, including the possibility for exposure at work or home and the possibility for exposing high-risk household members. Conversations about risk should take in to account the individual patient’s values and perceived risk of various outcomes and should respect and support autonomous decision-making (ACOG 2013).

Pregnant women who experience fever following vaccination should be counseled to take acetaminophen, as fever has been associated with adverse pregnancy outcomes. Acetaminophen has been proven to be safe for use in pregnancy and does not appear to impact antibody response to COVID-19 vaccines.

Pregnant patients who decline vaccination should be supported in their decision. Regardless of their decision to receive or not receive the vaccine, these conversations provide an opportunity to remind patients about the importance of other prevention measures such as hand washing, physical distancing, and wearing a mask.

Lactating Individuals

ACOG recommends COVID-19 vaccines be offered to lactating individuals similar to non-lactating individuals when they meet criteria for receipt of the vaccine based on prioritization groups outlined by the ACIP. While lactating individuals were not included in most clinical trials, COVID-19 vaccines should not be withheld from lactating individuals who otherwise meet criteria for vaccination. Theoretical concerns regarding the safety of vaccinating lactating individuals do not outweigh the potential benefits of receiving the vaccine. There is no need to avoid initiation or discontinue breastfeeding in patients who receive a COVID-19 vaccine.

Individuals Contemplating Pregnancy

Vaccination is strongly encouraged for non-pregnant individuals within the ACIP prioritization group(s). Further, ACOG recommends vaccination of individuals who are actively trying to become pregnant or are contemplating pregnancy and meet the criteria for vaccination based on ACIP prioritization recommendations. Additionally, it is not necessary to delay pregnancy after completing both doses of the COVID-19 vaccine.

If an individual becomes pregnant after the first dose of the COVID-19 vaccine series, the second dose should be administered as indicated. If an individual receives a COVID-19 vaccine and becomes pregnant within 30 days of receipt of the vaccine, participation in CDC’s V-SAFE program should be encouraged (see below for more information on CDC’s V-SAFE program).

Importantly, routine pregnancy testing is not recommended prior to receiving a COVID-19 vaccine.

Stakeholder COVID-19 Vaccine Emergency Use Agreement (EUA) FAQ

12/11/2020 Stakeholder COVID-19 Vaccine Emergency Use Agreement (EUA) FAQ

The CDC has shared an Emergency Use Authorization (EUA) FAQ for COVID-19 Vaccine Stakeholders. To view as a document, click here.


Will a prescription be necessary for a vaccine under an EUA?
As of December 9, 2020, no EUAs have been issued to authorize the use of COVID-19 vaccines. If EUAs are issued for COVID-19 vaccines, it is expected that those vaccines may be administered without the requirement for an individual prescription for each vaccine recipient from an authorized healthcare provider. Under an EUA, FDA has an option to waive prescription requirements, if appropriate, depending on the authorized product specifics, authorized use, and/or emergency circumstances. In addition to an EUA, other legal authorities and/or plans may apply to vaccine administration:

  • Legal authorities for relevant emergency response agencies (e.g., state, local, tribal and territorial health departments, healthcare professional licensing boards);
  •  Standing orders issued by a state health officer or applicable medical control officials or an executive order issued by a governor to authorize certain healthcare providers (e.g., nurses, pharmacists) to administer COVID-19 vaccine;
  • State COVID-19 vaccination and emergency response plans; and
  • DC’s COVID-19 Vaccination Program.

Does an EUA have any impact on standing orders?
Standing orders are a type of medical order authorized or allowed under state laws. They permit the delegation and delivery of healthcare services through standardized criteria and procedures. Standing orders are one mechanism to enable non-physician healthcare providers (e.g., nurses, pharmacists) to assess and vaccinate persons who meet the criteria for vaccination without requiring a direct, individual order each time.

During emergencies, states might use other legal mechanisms to facilitate vaccine administration, such as executive orders, emergency regulations, or position statements from licensing boards. FDA does not issue standing orders. However, it is expected that EUAs for COVID-19 vaccines would allow flexibility so that states could use their own mechanisms, like standing orders, to authorize appropriate healthcare providers to administer COVID-19 vaccine(s). States should review any applicable authorizations of certain healthcare providers to administer COVID-19 vaccine under the Public Readiness and Emergency Preparedness (PREP) Act Declaration for Medical Countermeasures against COVID-19 (e.g., qualified pharmacy technicians and state-authorized pharmacy interns acting under the supervision of a qualified pharmacist). It is also expected that vaccine administration would be in accordance with the stakeholder’s official COVID-19 vaccination and emergency response plans and that vaccination providers would be enrolled in the CDC COVID-19 Vaccination Program.

Statutes and regulations regarding the use of standing orders (or similar mechanisms) vary by state. States should review their statutory and regulatory language to ensure standing orders can cover the administration of an unlicensed vaccine that has been authorized by FDA for emergency use under an EUA. Specifically, states should ensure that state law does not preclude the use of standing orders for an investigational product authorized under an EUA. States should also ensure their state laws permit the administration of COVID-19 vaccines intended to be used under EUAs (i.e., the language of the state’s laws is either broad enough to include COVID-19 vaccines or specifically lists the COVID-19 vaccines, depending on how the state’s laws are written) and that COVID-19 vaccines are administered within the scope of authorized use under the applicable EUA.

Can a COVID-19 vaccine be administered to populations not included in the authorized use of the vaccine under its EUA?No. Use of any vaccine in populations outside the scope of its EUA

would be an unauthorized use of the vaccine. Each EUA issued by FDA will describe the scope of the vaccine’s authorized use, including populations (e.g., age groups) to which the vaccine may be administered. The scope of what is authorized under each EUA will be based on the available safety and efficacy data from populations studied in clinical trials.

In order for liability protections under the Public Readiness and Emergency Preparedness (PREP) Act to apply, the use of the vaccine must be under an appropriate regulatory mechanism (e.g., an EUA, investigational new drug application, or approved biologics license application). Therefore, if a vaccine is authorized for use under an EUA, any use beyond the scope of what is described in the EUA would not be eligible for applicable liability protections under the PREP Act or injury compensation available under the Countermeasures Injury Compensation Program.

CMS Acts to Ensure Coverage of COVID-19 Vaccines & Therapeutics

10/29/20 CMS Acts to Ensure Coverage of COVID-19 Vaccines & Therapeutics
Centers for Medicare & Medicaid Services (CMS) just released new Medicare payment rates for COVID-19 vaccine administration. The Medicare payment rates will be $28.39 to administer single-dose vaccines. For a COVID-19 vaccine requiring a series of two or more doses, the initial dose(s) administration payment rate will be $16.94, and $28.39 for the administration of the final dose in the series. These rates will be geographically adjusted and recognize the costs involved in administering the vaccine, including the additional resources involved with required public health reporting, conducting important outreach and patient education, and spending additional time with patients answering any questions they may have about the vaccine. Medicare beneficiaries, those in Original Medicare or enrolled in Medicare Advantage, will be able to get the vaccine at no cost.

Want updates sent right to your inbox? Email to join the Philadelphia Immunization Program’s COVID-19 vaccine mailing list.